News ASCO 25: AZ pitches upfront oral SERD use in breast cancer AstraZeneca stakes a claim to first-line treatment of HR+ breast cancer with its oral SERD, as Arvinas/Pfizer reveal their second-line data.
News ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC Gilead lays down a marker for AZ and Daiichi Sankyo to follow as Trodelvy scores in first-line treatment of triple-negative breast cancer (TNBC).
News ASCO 25: Roche places Itovebi marker in breast cancer Roche's Itovebi has become the first PI3K inhibitor to extend survival in HR-positive, HER2-negative breast cancer with a PIK3CA mutation.
News New data could move Enhertu into early breast cancer AstraZeneca and Daiichi Sankyo's Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage breast cancer for the first time.
News Enhertu poised to move first line in HER2+ breast cancer New data could make HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the first time.
News Trodelvy-Keytruda pairing hits the spot in breast cancer Gilead Sciences has cemented the role of its TROP2 drug Trodelvy in triple-negative breast cancer with a study win in combination with MSD's Keytruda.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.